Archive · 25 Nov 2025
Nippon India Pharma Fund Delivers Impressive Returns
The Nippon India Pharma Fund has been one of the top-performing mutual funds in India over the last 20 years.
It has delivered annualized returns of 18.26% through SIPs and 19.04% through lump sum investments.
If someone had invested Rs 1 lakh at the time of its launch, it would have grown to Rs 51.34 lakh in 21 years.
Similarly, a monthly SIP of Rs 10,000 would have grown to Rs 2.48 crore in the same period.
The fund invests in a mix of large and mid-sized companies in the pharma and healthcare industry, focusing on sectors with good growth potential and healthy cash flow.
Some of the top stocks in its portfolio include Sun Pharmaceutical, Divi’s Laboratories, and Lupin.
The fund has a total asset size of Rs 8,346.49 crore and an expense ratio of 1.80%.
Nippon India Pharma Fund has delivered 18.26% annualised returns through SIPs and 19.04% through lump sum investments over the last 20 years.
An investment of Rs 1 lakh at inception would have grown to Rs 51.34 lakh in 21 years.
A monthly SIP of Rs 10,000 would have grown to Rs 2.48 crore in 21 years.
The fund invests in a mix of large and mid-sized companies in the pharma and healthcare industry.
Top stocks in the portfolio include Sun Pharmaceutical, Divi’s Laboratories, and Lupin.
- Who
- Nippon India Pharma Fund
- What
- A mutual fund that has delivered impressive returns over 21 years
- When
- Launched on June 5, 2004
- Where
- India
- Why
- Invests in a mix of large and mid-sized companies in the pharma and healthcare industry
- Total assets
- Rs 8,346.49 crore (as of 31 October 2025)
- Expense ratio
- 1.80% (as of 31 October 2025)
- Standard deviation
- 15.24
- Beta
- 0.89
- Sharpe ratio
- 0.95
- Portfolio turnover
- 0.41
- NAV
- Rs 515.3218 (as of 21 November 2025)
